BARACLUDE
Total Payments
$418,745
Transactions
50
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $3,885 | 1 | 0 |
| 2020 | $3,885 | 1 | 0 |
| 2019 | $4.54 | 1 | 1 |
| 2018 | $182,381 | 16 | 0 |
| 2017 | $228,589 | 31 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $371,594 | 48 | 88.7% |
| Consulting Fee | $47,146 | 1 | 11.3% |
| Food and Beverage | $4.54 | 1 | 0.0% |
Payments by Type
Research
$371,594
48 transactions
General
$47,151
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PED Phase IIIB Pediatric Safety and Efficacy Study | E.R. Squibb & Sons, L.L.C. | $238,272 | 0 |
| Phase IV Large Simple Safety Study | E.R. Squibb & Sons, L.L.C. | $72,678 | 0 |
| PED Phase IIB Pediatric Efficacy Study | E.R. Squibb & Sons, L.L.C. | $23,759 | 0 |
| Office based screening for viral hepatits in Asian American communities | E.R. Squibb & Sons, L.L.C. | $12,940 | 0 |
| PED-Phase IIIB Pediatric Safety and Efficacy Study | E.R. Squibb & Sons, L.L.C. | $12,502 | 0 |
| Phase IV - Large Simple Safety Study | E.R. Squibb & Sons, L.L.C. | $5,214 | 0 |
| Phase IV - Large Simple Safety Study - Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | E.R. Squibb & Sons, L.L.C. | $3,885 | 0 |
| PED-Phase IIB Pediatric Efficacy Study | E.R. Squibb & Sons, L.L.C. | $2,345 | 0 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $418,745
Product Information
- Type Drug
- Total Payments $418,745
- Total Doctors 2
- Transactions 50
About BARACLUDE
BARACLUDE is a drug associated with $418,745 in payments to 2 healthcare providers, recorded across 50 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2022. In 2022, $3,885 was paid across 1 transactions to 0 doctors.
The most common payment nature for BARACLUDE is "Unspecified" ($371,594, 88.7% of total).
BARACLUDE is associated with 8 research studies, including "PED Phase IIIB Pediatric Safety and Efficacy Study" ($238,272).